High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification

Cancer

Volumn 101, Issue 5, 2004, Pages 1081-1089

  Laprie, Anne ^a,b   Michon, Jean ^c   Hartmann, Olivier ^d   Munzer, Caroline ^a   Leclair, Marc David ^e   Coze, Carole ^f   Valteau Couanet, Dominique ^d   Plantaz, Dominique ^f   Carrie, Christian ^g   Habrand, Jean Louis ^d   Bergeron, Christophe ^h   Chastagner, Pascal ⁱ   Défachelles, Anne Sophie ^j   Delattre, Olivier ^c   Combaret, Valérie ^h   Bénard, Jean ^d   Pérel, Yves ^k   Gandemer, Virginie ^l   Rubie, Hervé ^a  

^a HÔPITAL DES ENFANTS   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Hopital Mere Enfant CHU de Nantes   (France)

^f TIMONE HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ HÔPITAL D ENFANTS   (France)

^j CENTRE OSCAR LAMBRET   (France)

^k HÔPITAL PELLEGRIN   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

High dose chemotherapy; High risk neuroblastoma; MYCN; Pediatric; Radiation; Stem cell rescue

Indexed keywords

BUSULFAN; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG MEGADOSE; EXCISION; FOLLOW UP; FRANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; GAMMA RAYS; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; INFANT, NEWBORN; LYMPH NODES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; POSTOPERATIVE CARE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4143093843     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20453     Document Type: Article

References (40)

1. Miller RW, Young JL Jr., Novakovic B. Childhood cancer. Cancer. 1995;75:395-405.
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224:1121-1124.
3. Evans AE, Albo V, D'Angio GJ, et al. Factors influencing survival of children with nonmetastatic neuroblastoma. Cancer. 1976;38:661-666.
4. Mora J, Cheung NK, Chen L, Qin J, Gerald W. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer. 2001;91:435-442.
5. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1997;15:1171-1182.
6. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111-1116.
7. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256-1264.
8. Rubie H, Michon J, Plantaz D, et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Br J Cancer. 1998;77:2310-2317.
9. West DC, Shamberger RC, Macklis RM, et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol. 1993;11:84-90.
10. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:18-26.
11. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789-795.
12. Cheung NK, Heller G, Kushner BH, Burch L, O'Reilly RJ. Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. Prog Clin Biol Res. 1991;366:567-573.
13. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous bone marrow reconstitution. J Clin Oncol. 1984;2:609-616.
14. Dini G, Philip T, Hartmann O, et al. Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant. 1989;4(Suppl 4):42-46.
15. Dini G, Lanino E, Garaventa A, et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol. 1991;9:962-969.
16. Kushner BH, O'Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NK. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol. 1991;9:274-279.
17. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with Stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol. 1991;9:1037-1044.
18. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991; 38:393-424.
19. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993;11:2226-2233.
20. Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996;14:2504-2510.
21. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot 11 Study. J Clin Oncol. 2002;20:2284-2292.
22. Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant. 1997;20:543-551.
23. Philip T, Ladenstein R, Lasset C, et al. 1070 Myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997;33: 2130-2135.
24. Evans AE, August CS, Kamani N, et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. Med Pediatr Oncol. 1994;23:323-327.
25. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
26. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
27. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.
28. National Cancer Institute. Common Toxicity Criteria manual. Washington, DC: National Cancer Institute, 1997.
29. Evans AE, D'Angio GJ, Koop CE. The role of multimodal therapy in patients with local and regional neuroblastoma. J Pediatr Surg. 1984;19:77-80.
30. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995;31A:572-575.
31. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050-1058.
32. Garaventa A, Boni L, Lo Piccolo MS, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol. 2002;13:956-964.
33. Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. J Clin Oncol. 1993;11:1770-1779.
34. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Lipsanen M, Tapanainen P. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation. Bone Marrow Transplant. 1999;24:1131-1136.
35. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998;22:989-994.
36. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of Stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236-244.
37. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group Stage C neuroblastoma. J Clin Oncol. 1991;9:789-795.
38. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28-39.
39. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer. 2004;100:1268-1275.
40. Haas-Kogan DA, Fisch BM, Wara WM, et al. Intraoperative radiation therapy for high-risk pediatric neuroblastoma. Int J Radiat Oncol Biol Phys. 2000;47:985-992.